A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer. - A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated abvanced non-squamous NSCLC

Osaka Lung Cancer Study Group0 个研究点目标入组 40 人开始时间: 2010年6月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) squamous cell carcinoma 2) Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray 3) Pleural effusion, pericardial effusion and ascites to need treatment 4) Patients unable to take or unsupplied with folic acid and vitamin B12 5) Severe renal function disorder 6) SVC syndrome 7) Brain metastases with neurological symptoms 8) Active double cancer 9) Uncontrollable diabetes mellitus and hypertenson 10) Liver cirrhosis by image findings or laboratory examinations 11) History of severe heart disease (myocardial infarction within 6 months, unstable angina, post-PTCA or CAGB, signs of congestive heart failue, arrythmia with past history of heart failure, etc.) 12) Pregnancy, breast feeding and suspected pregnancy 13) History of grave drug allergic reaction 14) Acute inflammatory disease 15) An agreement is not obtained for support therapy such as transfusion etc 16) Having the bleeding tendency which is clinically apparent 17) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor

发起方

Osaka Lung Cancer Study Group